Pacer Advisors Inc. lifted its position in shares of Edwards Lifesciences Corp (NYSE:EW) by 10.2% during the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 23,038 shares of the medical research company’s stock after purchasing an additional 2,129 shares during the period. Pacer Advisors Inc.’s holdings in Edwards Lifesciences were worth $5,066,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Ledyard National Bank boosted its holdings in Edwards Lifesciences by 0.5% in the 2nd quarter. Ledyard National Bank now owns 9,178 shares of the medical research company’s stock valued at $1,696,000 after purchasing an additional 50 shares in the last quarter. Municipal Employees Retirement System of Michigan boosted its stake in shares of Edwards Lifesciences by 1.8% during the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 2,880 shares of the medical research company’s stock worth $532,000 after acquiring an additional 50 shares in the last quarter. Pitcairn Co. boosted its stake in shares of Edwards Lifesciences by 0.3% during the 2nd quarter. Pitcairn Co. now owns 18,756 shares of the medical research company’s stock worth $3,465,000 after acquiring an additional 51 shares in the last quarter. Tarbox Family Office Inc. boosted its stake in shares of Edwards Lifesciences by 48.7% during the 2nd quarter. Tarbox Family Office Inc. now owns 177 shares of the medical research company’s stock worth $33,000 after acquiring an additional 58 shares in the last quarter. Finally, Advisory Services Network LLC boosted its stake in shares of Edwards Lifesciences by 0.4% during the 2nd quarter. Advisory Services Network LLC now owns 14,932 shares of the medical research company’s stock worth $2,759,000 after acquiring an additional 59 shares in the last quarter. Institutional investors and hedge funds own 81.53% of the company’s stock.
Several equities research analysts have recently commented on EW shares. ValuEngine lowered Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. Morgan Stanley boosted their price target on Edwards Lifesciences from $210.00 to $228.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 24th. JPMorgan Chase & Co. boosted their price target on Edwards Lifesciences from $190.00 to $225.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 24th. Zacks Investment Research raised Edwards Lifesciences from a “hold” rating to a “buy” rating and set a $232.00 price target on the stock in a research note on Thursday, July 25th. Finally, Barclays boosted their price target on Edwards Lifesciences from $160.00 to $175.00 and gave the stock an “underweight” rating in a research note on Wednesday, July 24th. Two research analysts have rated the stock with a sell rating, five have issued a hold rating and thirteen have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $213.33.
Shares of EW opened at $227.11 on Friday. The stock has a fifty day moving average of $219.92 and a two-hundred day moving average of $197.32. The company has a debt-to-equity ratio of 0.18, a quick ratio of 2.48 and a current ratio of 3.38. The company has a market capitalization of $47.23 billion, a PE ratio of 48.32, a price-to-earnings-growth ratio of 2.83 and a beta of 0.84. Edwards Lifesciences Corp has a fifty-two week low of $136.44 and a fifty-two week high of $230.19.
Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Tuesday, July 23rd. The medical research company reported $1.38 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.33 by $0.05. The company had revenue of $1.09 billion during the quarter, compared to the consensus estimate of $1.04 billion. Edwards Lifesciences had a return on equity of 31.25% and a net margin of 18.29%. Edwards Lifesciences’s revenue was up 15.2% on a year-over-year basis. During the same period in the previous year, the firm posted $1.24 EPS. As a group, equities research analysts forecast that Edwards Lifesciences Corp will post 5.34 earnings per share for the current fiscal year.
In other news, CEO Michael A. Mussallem sold 22,850 shares of the company’s stock in a transaction on Thursday, August 22nd. The stock was sold at an average price of $216.70, for a total transaction of $4,951,595.00. Following the completion of the sale, the chief executive officer now directly owns 95,770 shares in the company, valued at approximately $20,753,359. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, VP Catherine M. Szyman sold 1,152 shares of the company’s stock in a transaction on Monday, July 15th. The stock was sold at an average price of $191.70, for a total value of $220,838.40. Following the sale, the vice president now owns 19,162 shares of the company’s stock, valued at $3,673,355.40. The disclosure for this sale can be found here. Insiders sold a total of 155,822 shares of company stock valued at $33,641,784 over the last quarter. 1.63% of the stock is currently owned by insiders.
About Edwards Lifesciences
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.
Featured Article: How can you know how many shares are floating?
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.